Quantifying Fetal Reprogramming for Biomarker Development in the Era of High-Throughput Sequencing
Gestational hypertensive disorders continue to threaten the well-being of pregnant women and their offspring. The only current definitive treatment for gestational hypertensive disorders is delivery of the fetus. The optimal timing of delivery remains controversial. Currently, the available clinical...
Main Authors: | Fu-Sheng Chou, Krystel Newton, Pei-Shan Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/12/3/329 |
Similar Items
-
The SLC25A42 Transcript Is a Biomarker for Fetal Reprogramming in Response to Placental Insufficiency in Preterm Newborns Under 32 Weeks Gestation—A Pilot Study
by: Fu-Sheng Chou, et al.
Published: (2020-08-01) -
THE EFFECT OF HUMORAL FACTORS RELEASED BY HYPOPERFUSED PLACENTA ON FETAL DEVELOPMENT
by: Vladimir Gureev, et al.
Published: (2015-12-01) -
Inflammasomes—A Molecular Link for Altered Immunoregulation and Inflammation Mediated Vascular Dysfunction in Preeclampsia
by: Padma Murthi, et al.
Published: (2020-02-01) -
BIOMARKER TERKINI DALAM USAHA MEMPREDIKSI PREEKLAMPSIA
by: Yosef Dwi Cahyadi Salan
Published: (2017-05-01) -
Placenta-derived exosomes: potential biomarkers of preeclampsia
by: Pillay P, et al.
Published: (2017-10-01)